-
Kenya's economy faces climate change risks: World Bank
-
Venezuelan student freed after months in US immigration custody
-
US mulls lifting sanctions on Iranian oil at sea despite war on Tehran
-
IMF raises concern over global inflation, output over Iran war
-
Iran attacks on gas and oil refineries heighten fears over war fallout
-
Call to add Nazi camps to UNESCO list
-
'Miracle': Europe reconnects with lost spacecraft
-
Nigeria 'challenged by terrorism', president says on UK state visit
-
EU summit fails to rally Orban behind stalled Ukraine loan
-
What we know about the UK's deadly meningitis outbreak
-
What cargo ships are passing Hormuz strait?
-
Defiant Orban digs in over blocked Ukraine loan at EU talks
-
Tokyo's dazzling cherry blossom season officially begins
-
Energy prices surge, stocks sink amid rising energy shock fears
-
Baby monkey Punch acclimatising, making new friends at Japan zoo
-
Labubu creators hope for monster film hit in Sony co-production
-
Patching the wounds of Kinshasa's street children
-
Strait of Hormuz blockage drives up Gulf food bills
-
Mideast energy shock rattles eurozone rate-setters
-
Iran targets Gulf energy sites after gas field strike
-
Music popstar will.i.am meshes AI and 'micromobility'
-
US Fed Chair says 'no intention' of leaving board while probe ongoing
-
Iran targets Gulf energy sites after intel chief killed
-
Cesar Chavez, icon of US labor movement, accused of serial sex abuse: report
-
Iran suffers new blow as Israel kills intel chief
-
Slovakia curbs diesel sales, ups prices for foreigners
-
US Fed holds rates unchanged over 'uncertain' Iran war implications
-
Billionaire Dyson buys 50 percent stake in Bath rugby
-
The platypus is even weirder than thought, scientists discover
-
How many cargo ships are passing Hormuz strait?
-
Oil surges as Iran gas facilities hit, stocks slide
-
Chilean GDP beats 2025 forecast despite mining dip
-
Storms, warm seas drove sudden drop in Antarctic ice: study
-
Global music market grows, calls for AI compensation: industry body
-
Belgian court suspends TotalEnergies climate trial
-
Troubled waters: Thai fishermen marooned by rising fuel costs
-
Nigerian president meets royals on 'historic' UK state visit
-
Why convoys cannot fully protect oil tankers from Iran attacks
-
Oil wavers, stocks rise as attention turns to US Fed
-
China tech giant Tencent bets on AI agents
-
Israelis shelter with pets from threat of Iran missiles
-
Deadly strikes across Mideast as Iran vows revenge on slain security chief
-
Brussels to unveil 'EU Inc' pan-European company status
-
Brazil starts to restrict minors' access to social media
-
US Fed expected to hold rates steady as Iran war's shockwaves ripple
-
Oscars audience drops, viewing figures show
-
Affiliate of Pacific Avenue Capital Partners Completes Acquisition of Care.com from IAC
-
Nvidia says restarting production of China-bound chips
-
US airlines still see strong demand as jet fuel worries loom
-
Milei blasts Iran on anniversary of attack on Israeli embassy
Canada health authority approves Pfizer's anti-Covid pill
Canada's health authority said Monday it has approved Pfizer's anti-Covid pill, Paxlovid, for adults at high risk of progressing to serious disease.
The oral treatment was approved after an "expedited review," Health Canada said in a statement on its website, adding that it would continue to monitor its safety and effectiveness.
"No drug, including PAXLOVID TM, is a substitute for vaccination," the statement added.
The drug, which comprises two types of tablet, is the first Covid-19 therapy which can be taken at home, and is potentially a huge step towards ending the pandemic.
"Today's announcement is particularly important as access to easy-to-use treatments could help to reduce the severity of Covid-19 in adults who become newly infected and are at high-risk of progressing to serious illness," said Theresa Tam, Canada's chief public health officer.
The approval comes as Canada, like many countries, has been struggling to contain the Omicron variant of Covid-19.
The French-speaking province of Quebec recently announced it would levy a tax on the unvaccinated, arguing they impose a burden on everyone else.
Paxlovid has so far been authorized in a handful of countries including the United States and Israel, while the European Union has allowed member states to use it ahead of formal approval as an emergency measure against Omicron.
Unlike vaccines, it does not target the ever-evolving spike protein which the coronavirus uses to invade cells.
It should therefore in theory be more variant-proof, and the company has said preliminary lab studies have backed up that hypothesis.
S.F.Lacroix--CPN